Clinical trials
IPF clinical trials
Below are recruiting ipf clinical trials, each written for real people, not researchers. We’re tracking 46 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07194382RecruitingPhase 2
Testing a new liquid form of nintedanib for IPF
This trial tests a liquid version of the medication nintedanib (AP02) to see if it is safe and works well for people with idiopathic pulmonary fibrosis (IPF). If you have IPF and have not taken nintedanib or pirfenidone recently, you may be able to join.
Camperdown, New South WalesAges 40 years+ - NCT06747923RecruitingPhase 2
SB17170 for Idiopathic Pulmonary Fibrosis (IPF)
This trial tests a new drug, SB17170, for people with IPF. It aims to see if the drug can help slow down lung damage. You may be eligible if you have a confirmed diagnosis of IPF and meet certain lung function criteria.
GoyangAges 40 years+ - NCT06914713Recruiting
Jin-shui Huan-xian formula to slow lung decline in IPF
This study tests an herbal formula (Jin-shui Huan-xian) to see if it can slow the worsening of lung function in people with idiopathic pulmonary fibrosis (IPF). It may be an option for those with mild-to-moderate lung impairment.
Zhengzhou, HenanAges 40–85 - NCT07790614Recruiting
Comparing two CT scan methods for identifying pulmonary fibrosis
This study compares two types of CT scans to see which one is better at identifying idiopathic pulmonary fibrosis (IPF), a specific type of interstitial lung disease. You may be able to join if you have been diagnosed with ILD and are being discussed by a team of specialists.
Rozzano, ItalyAges 18 years+ - NCT07652658RecruitingPhase 2
Study of AZD8965 for people with IPF
This trial tests a new drug called AZD8965 for Idiopathic Pulmonary Fibrosis (IPF). It aims to see if the drug can help people with IPF either on current treatments or not on standard therapy.
Birmingham, AlabamaAges 40 years+ - NCT03418350Recruiting
Study how acid reflux may affect lung scarring
This trial studies whether reflux (acid moving up toward the throat) plays a role in idiopathic pulmonary fibrosis (IPF), a condition where lung tissue becomes scarred. It may help doctors understand triggers that could worsen symptoms and guide more targeted care.
Denver, ColoradoAges 40–95 - NCT07464912RecruitingPhase 3
Testing TDI01 for idiopathic pulmonary fibrosis
This trial tests a new drug called TDI01 to see if it helps people with idiopathic pulmonary fibrosis (IPF), a lung disease that causes scarring. You may qualify if you have a confirmed IPF diagnosis and your lung function is stable enough.
Beijing, Beijing MunicipalityAges 40–80 - NCT07332117Recruiting
Studying body changes in IPF and PPF patients starting anti-fibrotic drugs
This study uses safe, painless scans (like muscle ultrasound and a body composition test) to track changes in muscle and fat in patients with IPF or PPF who are starting anti-fibrotic medication. The goal is to better understand how these treatments affect your body.
LondonAges 18 years+ - NCT07284602RecruitingPhase 3
Comparing a new drug to pirfenidone for lung scarring
This trial tests a new medicine, LYT-100 (deupirfenidone), against the standard drug pirfenidone for people with idiopathic pulmonary fibrosis (IPF). It aims to see if the new drug works better or has fewer side effects.
Palm Spring, CaliforniaAges 40 years+ - NCT06756230Recruiting
Downhill walking exercise for IPF patients
This study tests whether downhill walking improves lung function and exercise ability in people with idiopathic pulmonary fibrosis (IPF). If you can walk on a treadmill and haven't been in a structured exercise program recently, you may qualify.
Istanbul, ÜsküdarAges 18–75 - NCT07082842RecruitingPhase 3
Testing HEC585 tablets for idiopathic pulmonary fibrosis
This trial tests a new tablet, HEC585, for people with idiopathic pulmonary fibrosis (IPF). It aims to see if the drug can help improve lung function and slow the disease. Participants must have a confirmed IPF diagnosis and meet specific breathing test results.
Beijing, Beijing MunicipalityAges 40–80 - NCT06968845RecruitingPhase 2
Study of LTI-03 for Idiopathic Pulmonary Fibrosis
This trial tests an inhaled drug called LTI-03 to see if it can help people with idiopathic pulmonary fibrosis (IPF). It may be an option for those with moderate lung function who are stable on their current treatment.
Birmingham, AlabamaAges 40 years+ - NCT07869147RecruitingPhase 2
Study of ORJ-001 for idiopathic pulmonary fibrosis
This trial tests a new medicine, ORJ-001, for people with idiopathic pulmonary fibrosis (IPF), a lung condition that causes scarring. The goal is to see if it can help slow the disease and improve breathing.
Doral, FloridaAges 40 years+ - NCT05193136Recruiting
Testing sleep and exercise effects on strength and thinking in lung disease
This trial studies whether improving sleep habits can help people with lung conditions like COPD or IPF maintain muscle strength and thinking (cognitive function). It may help by addressing sleep quality and related health factors, but eligibility depends on your current diagnoses and treatments.
Jōyō, KyotoAges 20 years+ - NCT04442711Recruiting
Study of worsening lung symptoms in people with IPF
This study looks at people with idiopathic pulmonary fibrosis (IPF) who are currently having a sudden worsening of breathing symptoms. It may help doctors better understand what happens during these flare-ups and how to manage them.
Hellerup, CopenhagenAges 18 years+ - NCT07868419RecruitingPhase 3
Nalbuphine tablets for chronic cough in pulmonary fibrosis
This trial tests an extended-release tablet called nalbuphine to reduce chronic coughing in people with idiopathic pulmonary fibrosis (IPF), a lung condition that causes scarring and often leads to a persistent cough. If you have IPF and have been coughing for at least 8 weeks, this study may help manage that symptom.
Wilmington, DelawareAges 40 years+ - NCT07723872Recruiting
Finger vs. earlobe oxygen test during a 6-minute walk
This study compares oxygen levels measured at the finger versus the earlobe during a 6-minute walk test for people with interstitial lung disease. It helps find the most accurate way to monitor your oxygen during exercise.
Granollers, SpainAges 18 years+ - NCT07707245Recruiting
Finding biomarkers in lung disease and lung cancer
This trial studies blood and tissue samples from people with COPD, IPF, or lung cancer to find markers that can help diagnose and predict these conditions. It aims to discover why some lung diseases progress to cancer.
Milan, MilanAges 18 years+ - NCT07687459RecruitingPhase 3
Oral treatment for idiopathic pulmonary fibrosis
This trial tests an experimental pill called rentosertib for people with idiopathic pulmonary fibrosis (IPF), a lung disease that causes scarring. The study aims to see if the drug can slow down the disease and improve breathing.
Hefei, AnhuiAges 40 years+ - NCT07671911RecruitingPhase 3
Cough relief for pulmonary fibrosis
This trial tests a new extended-release medicine, nalbuphine, to reduce chronic coughing in people with idiopathic pulmonary fibrosis (a lung disease that scars the lungs). It may help make cough less frequent and less bothersome.
Newport Beach, CaliforniaAges 40 years+ - NCT07679893RecruitingPhase 2
Inhaled nintedanib for idiopathic pulmonary fibrosis
This trial tests an inhaled form of nintedanib (a drug that helps slow lung scarring) for people with idiopathic pulmonary fibrosis (IPF). It may be an option for those newly diagnosed or already on stable treatment.
Windsor, OntarioAges 40–80 - NCT07673237Recruiting
Remote monitoring for interstitial lung disease
This study tests whether using remote monitoring devices and apps at home can help track your lung health between clinic visits. It may help you stay connected with your care team and catch changes sooner.
San Francisco, CaliforniaAges 18 years+ - NCT06125327RecruitingPhase 2/Phase 3
SC1011 for idiopathic pulmonary fibrosis (IPF)
This trial tests a new medication called SC1011 taken twice a day, compared to a placebo, to see if it can help people with IPF. It is for patients who were diagnosed within the last 5 years and have moderate lung function.
Beijing, Beijing MunicipalityAges 40–80 - NCT07486206Recruiting
Optimizing follow-up for interstitial lung disease
This trial tests a new way to organize follow-up visits for people with interstitial lung disease (a group of lung conditions). It aims to make care simpler and more effective for patients who are already on treatment.
Granollers, BarcelonaAges 18 years+
Hear when a new IPF trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for ipf?
- Yes. Clin2 currently lists 46 recruiting ipf studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a ipf trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a ipf trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.